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Abstract
Background: Bacteremic pneumococcal pneumonia (BPP) is the most common clinical presentation
of invasive pneumococcal disease (IPD). Although it has been extensively studied, there is little
knowledge in our region in relation to burden of disease, demographic and outcome features.
Methods: We conducted a prospective, longitudinal, observational study from 1989 to 2015 in adult
patients with BPP, in order to deepen our knowledge of the characteristics of this disease in our
community hospital in Tandil, Argentina.
Results: 279 patients were included. The mean incidence was 2.8/1000 admissions with a sharp
decrease in the last two years, reaching 0.8/1000 admissions. Mean patient age was 60 years.
Comorbidities were found in 65% of the cases. Non-respiratory symptoms occurred in 50% of cases.
Infiltrates on chest x ray were predominantly unilateral (75%) and lobar (57%). Regarding severity,
a low PSI score I-II-II was found in 178 patients (64%), 60 (22%) were admitted to ICU, 40 (14%)
required mechanical ventilation, and 21 (8%) developed empyema. Penicillin resistance was not
found. Mortality was 18% (49/279), and by a multivariate analysis it was associated with confusion
(OR= 5.44), age>80 years (OR =5.72), leukopenia (OR =5.73) and dyspnea (OR=7.87).
Conclusions: In this study of 279 bacteremic pneumococcal pneumonia we reinforce previous
knowledge on this disease regarding incidence and clinical features and confirm a considerable an
early mortality associated to age and severity of disease at onset. Recent changes in incidence of
BPP in adults could be secondary to herd effect of PVC 13 a vaccine that is mandatory in children in
our community since 2012.

Introduction
Streptococcus pneumoniae (S. pneumoniae) is the most
common cause of community acquired pneumonia (CAP) in
adults accounting for most cases of pneumonia hospitalizations
and deaths [1-2]. Bacteremic pneumonia is the most frequent
invasive pneumococcal disease (IPD) in adults and remains a
major cause of morbidity and mortality despite improvements in
medical care [2-3]. From older and recent studies, it is estimated
that approximately 20% of patients with pneumococcal
pneumonia develop bacteremia [3-4], with a mortality rate
ranging between 15-35%.
More than 50% of S. pneumoniae bacteremia cases occur in
elderly patients and most studies show increased pneumococcalrelated deaths in this population [1-3-5]. Variations between
reported fatality rates might be explained by differences between
studied populations including demographic factors, underlying
health conditions, severity of illness at the time of admission,
and bacterial factors. Also, geographical and temporal situations
should be considered. On the other hand,
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drug resistance does not appear to contribute to mortality or
ICU admission rates [5].
Despite the fact that BPP is a frequent and severe disease, there
is minimal information regarding BPP in our city. We report
here the result of 26-year prospective study in patients with BPP
treated in our hospital, to assess local disease incidence, clinical,
radiographic and microbiological features, as well as to evaluate
factors related to mortality.

Methods
Study Design and Study Population
This was a longitudinal, prospective observational study of
adult patients with BPP evaluated at the Santamarina Hospital
in the city of Tandil. The hospital is a 130-bed primary care
community hospital. Tandil is a city with a population of
130,000 inhabitants located in the province of Buenos Aires,
Argentina.
Inclusion/exclusion criteria
Inclusion criteria: Patients 18 years or older with BPP that were
assisted in the emergency room and admitted to the hospital or
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treated in ambulatory setting between 1989 and 2015.
Exclusion criteria: having been hospitalized in the last 30 days,
or presented with any other evidence suggestive of nosocomial
pneumonia, severe immunosuppression such in transplantation,
AIDS or receiving chemotherapy or other immunosuppressive
drugs.
Study definitions/variables
Pneumonia was defined as the presence of a new infiltrate on
chest radiograph plus two or more of the following clinical
manifestations including: fever (axillary temperature >37.8ºC),
cough, production of purulent sputum, pleuritic chest pain and
dyspnoea. BPP was defined as a diagnosis of pneumonia with
one or more positive blood cultures for S. pneumoniae.
Identification of patients with BPP: one of the authors of this
manuscript, (CH or JG), or a resident, reviewed admissions to
the hospital daily, including holidays. The laboratory informed
as soon as possible, when S. pneumoniae was isolated from blood
culture. Data of chart was reviewed and a form was completed
within 48-72h of admission. All patients were questioned,
examined and followed exclusively by the authors. (JG or CH).
When a patient with criteria of BPP was not admitted and sent
home we strived to contact him in order to assist and include
him in the study.
Hospital based incidence was calculated dividing number of
BPP/adult patients admitted annually to the hospital x 1000.
Seasonal distribution was registered. Population incidence, was
calculated during the period 2010- 2015, adding to our series of
patients with BPP admitted to the other two centres of the city,
and considering population variations in the period.
The following variables were recorded on admission directly
from the subject, or from documentation in chart or interview
with relatives: age, sex, duration of illness before consult,
underlying chronic conditions such as diabetes, chronic renal
failure, congestive heart failure, chronic lung disease, neurologic
disease, malignancies, HIV infection, alcoholism, hepatic
disease, smoking, prior antimicrobial therapy as well as clinical
signs and symptoms. Living in nursing home or homelessness
was registered too.
Patients with dull percussion and bronchial breathing sounds on
auscultation were considered as having clinical consolidation.
Hypotension was defined as systolic arterial tension below
90mmHg. Abdominal pain, vomiting, hypotension, and
confusion were considered nonpulmonary symptoms.
Classical pneumococcal infection was considered if patients
had all four of the following features: fever, pleuritic chest pain,
lobar consolidation on chest X ray and leucocytosis. Pleural fluid
examination was performed in all patients with pleural effusion.
Empyema was considered when macroscopic pus or bacteria
were identified in pleural fluid.
History of pneumococcal vaccination was recorded in all cases
and considered positive in patients who had received at least a
single dose of 23-valent pneumococcal polysaccharide vaccine
within the last 5 years. On admission, patients were stratified
into risk classes I to V based on Pneumonia Severity Index (PSI)
score [6].

Laboratory
Leukocytosis was considered when white blood cells were more
than 12,000/ml and leukopenia when WBC <4,000/ml
Microbiological Testing
S. pneumoniae was identified using standard microbiology
procedures. One set of blood cultures were collected from
each patient at entry, which is considered standard of care for
patients with CAP admitted to the hospital.
Conventional broth culture using nutritionally enriched media
was used until 1997, after which fully automated, continuous
blood culture monitoring equipment (BacT/ALERT® 3D
BioMérieux, Inc. 100 Rodolphe Street, Durham, NC) became
available. High quality sputum specimens (containing <10
squamous epithelial cells and >25 Polymorph Nuclear cells per
low power field) were processed for bacterial diagnosis. Briefly,
sputum was homogenized in 1.2 ml of sterile saline, spread onto
a glass slide, air dried and heat fixed. Strains were identified
based on Gram stains and morphology: gram-positive cocci
found in singles, in pairs or in short chains were indicative of
pneumococci infection. Sputum samples were inoculated on
blood agar and chocolate agar plates and incubated at 35ºC
with 5-10% CO2 for 72 hours. All S. pneumoniae isolates were
tested for penicillin susceptibility by diffusion, using 1 µg
oxacillin disks and by broth micro-dilution test. Isolates were
also screened for susceptibility to erythromycin, tetracycline,
and levofloxacin using disk diffusion method. In addition,
minimum inhibitory concentration (MIC) tests were used to
determine susceptibility to erythromycin, extended spectrum
cephalosporins, fluoroquinolones, tetracycline, trimethoprim
sulfametoxazol, clindamycin, cefuroxime and vancomycin,
in accordance to Clinical and Laboratory Standards Institute
(CLSI, 2012) established guidelines [7].
Radiology
Images on chest radiograph were classified by one of the
investigators (JG) according to pattern (lobar consolidation,
interstitial infiltrate, bronchopneumonia, pleural effusion) and
extension (number of lobes affected, bilateral involvement)
Outcome
Patient were followed for 30 days after diagnosis, and
complications were recorded, namely: pleural effusion,
empyema, admission to ICU and need of mechanical ventilation.
Overall case fatality rate was defined as death due to any
cause within 30 days of hospitalization. Overall case fatality
rate was defined as death due to any cause within 30 days of
hospitalization.
Statistical Analysis
Qualitative variables are presented as the mean and range(minmax), while categorical variables are presented as frequency and
percent. Contingency tables were used to measure associations
with calculation of the chi-squared or Fisher’s exact test, and
odds ratio (OR) were estimated. Multiple logistic regression
analyses was performed to evaluate those factors found to be
significant by univariate analysis and previously hypothesized
to affect mortality. Two-tailed p-values are reported, with
statistical significance when p<0.05. SAS V9.3 statistical
software was used for calculations (SAS, Institute Inc. Cary, NC,
USA).
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Figure 1 Number of cases of BPP between 1989-2015 (n=279)

Results

Table 1B Patient characteristics of study population. Differences between
survivors and mortalities by univariate analysis.

Epidemiology: 279 patients were included. Distribution of cases
showed a sporadic pattern along the study ranging from 3 to 30
cases per year Figure 1. A decrease of 50% was observed in the
last two years of the study. Hospital-based incidence of BPP was
2.1 cases/1,000 admissions and population-based incidence
was 11.8 per 100,000 person-years (95% CI, 11.65-12.01), while
38% of episodes occurred in winter. The mean time from onset
of illness to hospital admission was 2.9 days (1.15).
Two patients, the only individuals who had received
antipneumococcal vaccine, both with humoral immunodeficiency
multiple myeloma and hypogammaglobulinemia, had recurrent
episodes of BPP.
The main demographic, comorbidities, clinical findings,
radiographic, laboratory, severity and outcome features of
patients are showed in Table 1A and Table1B.
Table 1A Main characteristics of study population. Differences between
survivors and mortalities by univariate analysis.
Total number of
patients
Demographics
Mean age
18-50
50-65
65-80
>80
Males/females
Females
Comorbidities
One or more
Cigarette smoking
COPD
CHF
Alcoholism
Diabetes
Liver disease
Malignancy
Neurologic disease
Renal failure
HIV infection
Physical Examination
Fever
Cough
Dyspnoea
Chest pain
Consolidation
Expectoration
Hypotension
Confusion
Abdominal Symptoms
Non-pulmonary
Symptoms

Study Population

Survivors

Mortalities

279

230

49

70(92.1)
68(83.9)
69(83.1)
23(58.9)

6(7.89)
13(16)
14(16.8)
16(41)

180(64.5)
75(26.8)
51(18.09)
47(16.85)
44(15.77)
28(10.04)
21(7.53)
20(7.17)
19(6.91)
9(3.23)
5(1.79)

144 (62.61)
64(27.83)
13(5.65)
15(6.52)
5(2.17)
3(1.30)
4(1.74)
5(2.17)
5(2.17)
3(1.30)
4(1.73)

36(73.47)
11(22.45)
38(77.55)
32(65.31)
39(79.59)
25(51.02)
17(34.69)
15(30.61)
14(28.57)
6(12.24)
1(2.04)

0.1491
0.44
0.0998
0.0046
0.2390
0.4353*
0.0771*
0.3635*
0.3451*
0.1970*

212(75.99)
158(56.63)
140(50.8)
114(40.86)
105(37.6)
79(28.32)
79(28.3)
55(19.7)
59(17.9)

186(80.8)
139(60.4)
98(42.6)
106(46)
94(40.8)
70(30.4)
56(24.3)
34(14.7)
43(24.7)

26(53)
19(38.7)
42(85.7)
8(16.3)
11(22.4)
9(18.3)
23(46.9)
21(42.8)
7(14.2)

<0.0001
0.005
0.0001
0.0001
0.01
0.08
0.0015
<0.0001
0.26

31(43)

0.0131

59.7 SD+18.42
76(27.24)
81(29.03)
83(29.74)
39(13.9)
177
102

139(50)

Fisher Exact test*
COPD-Chronic obstructive pulmonary disease

108(47)
CHF-Congestive heart failure

Total number of patients
Radiographic findings
Unilateral infiltrate
Bilateral infiltrate
Lobar
Diffuse
Pleural effusion
Laboratory
Mean Hematocrit
White blood cells
Leukocytosis
Leukopenia
Severity
PSI Score I
PSI Score II
PSI Score III
PSI Score IV
PSI Score V
PSI Score I-II-III
PSI Score IV+V
Complications
ICU admission
Mechanical Ventilation
Empyema

Study Population
279

Survivors
230

Moratlities
49

Pvalue

209(74.91)
56(24.35)
160(57.34)
102(36.55)
49(17.56)

178(77.39)
40(17.39)
143(62.17)
76(33.04)
40(17.39)

31(63.26)
16(41.02)
17(34.69)
26(53.06)
9(18.36)

0.0384
0.0154
0.0006
0.0057
0.8705

37.7(16-59)
16800 (900-44700)
177(63.44)
28(10.03)

17276
156(67.82)
14(6.08)

13247
21(42.85)
14(28.57)

0.0010
<0.0001

47 (16.84)
71(25.44)
60(21.5)
94(33.69)
7(2.5)
178(63.7)
101(36.2)

167(72.6)
52(22.60)

11(22.4)
38(77.55)

<0.0001
<0.0001

60(21.50)
40(14.33)
21(7.52)

32(13.9)
14(6.08)
18(7.82)

28(57.14)
26(53.06)
3(6.12)

<0.0001
<0.001
0.707

The classic association of fever, chest pain, leukocytosis and
lobar consolidation was present in 35 patients (14%), all of
whom survived.

Pvalue

Non-pulmonary symptoms as abdominal pain, confusion and
hypotension were present in 50% of cases. In 3 cases there was
associated meningitis, and in one case purulent pericarditis.
<0.0001

PSI-Pneumonia severity index

Antibiotic treatment: Ninety five percent of BPP cases admitted
to the hospital received monotherapy and 5% combined
therapy. Fifteen patients were managed as outpatients, and
treated with oral antibiotics as amoxicillin, clarithromycin,
and fluoroquinolones, or intramuscular ceftriaxone. βetalactam antibiotics (cefotaxime, ceftriaxone, ampicillin, ampi/
sulbactam) were used in 93% of patients.
Mortality: 49 patients died, resulting in an overall mortality rate
of 16.7%: 27 deaths (55%) occurred within the first 3 days of
hospitalization. Mean time elapsed between hospital admission
and death was 5.2 days (median time 3 days) and there was an
increment of death with age. Factors found to be significantly
associated with mortality in univariate analyses were: age
>80 years, dyspnea, hypotension, confusion, nonpulmonary
symptoms, bilateral and diffuse infiltrates on chest radiograph,
leukopenia, and high PSI score. Conversely, fever, chest pain
and lobar infiltrates were significant predictors of survival.
Multivariate analysis is shown in Table 2.
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Table 2 Multivariate analysis of variables potentially associated with
mortality

Factor
OR
(95% CI)
Fever
0.292 (0.13-0.66)
Chest pain
0.3619 (0.13-0.95)
Age of >80 years 4.03 (1.55-10.49)
Confusion
5.43 (2.24-13.19)
Leukopenia
6.27 (2.24-18.38)
Dyspnea
8.58 (3.20-23.04)

P
0.0033
0.04
0.0042
0.0002
0.0008
<0.0001

Microbiology: All pneumococcal strains were found to be
susceptible to penicillin (MIC=0.006-2 µg/ml) and ceftriaxone
(MIC =0.012 to 0.019 µg/ml). Percentages of resistance to other
antibiotics were: erythromycin 8.1% (MIC =0.064 – 256 µg/ml),
clindamycin 6.4% (MIC= 0.024-128 µg/ml), doxycycline 6.9%
(MIC=0.5-64.0 µg/ml). Resistance rate to fluoroquinolones
(levofloxacin) remained low 2.8% (MIC=0.38-8.00 µg/ml).
Only 4 patients had S. pneumoniae isolated simultaneously
in sputum and blood. One case of BPP and simultaneous
pulmonary tuberculosis was detected.

Discussion
In this study of 279 patients with bacteremic pneumococcal
pneumonia we confirm a considerable early mortality associated
to increased age and increased severity of disease at time of
presentation.
Overall annual rate of BPP in this study population was
11.8 cases/100,000 person-years, which is in agreement with
other published results [8-10]. The reduction in the last two
years could be secondary to herd effect of PVC 13, a vaccine that
is mandatory in children in our city since 2012. The average age
of 60 years found for the patients in our study is comparable to
the mean age in other studies (range between 52 and 64 years
old)[5,8,11].
Regarding underlying conditions and in agreement with
previous published results, cigarette smoking, was the most
prevalent risk factor, followed by chronic obstructive lung
disease and congestive heart failure [10,12,13]. In fact, current
cigarette smoking was predictive of BPP in one study [8] and
was associated to septic shock in another [14].
Interestingly, one third of the patients had no evidence of any
predisposing condition for BPP. We believe that this group
deserves to be exhaustively evaluated in order to gain knowledge
in the prevention of IPD.
Clinical manifestations were similar to those reported in the
literature [12,15], except for sputum production which was
less frequent: only 30% of the patients with BPP presented
this symptom and this fact has been observed by others
[16,17]. Isolation of S. pneumoniae from sputum specimens
was very uncommon in our population. This can be related to
early hospital admission or to differences in BPP and non-BPP
pathophysiology [18].
Classical presentation with fever, chest pain, leukocytosis
and lobar pattern on chest radiograph, although uncommon,
showed significant correlation to better outcome.

Almost half of the patients had nonpulmonary symptoms from
onset, so it is important to consider hemodynamic, abdominal
or neurological manifestations in patients at risk for IPD in
order to ensure prompt diagnosis and treatment [19].
As has been previously described most patients with BPP
presented marked leukocytosis and neutrophilia. Leukopenia,
although less frequent, was significantly related to worst
outcome, as others investigators have observed [18,20].
In agreement with already published large series of patients
[5,21,22] the presence of bacteremia was not associated with
severity of illness, since most patients presented low PSI score
(classes I-III). Even though the PSI score was not originally
designed as a prognostic tool for BPP, it can be used to define
illness severity because, although less specific, it is still more
sensitive than other scores for BPP-related risk of death [23].
Surprisingly, patients in the low score risk group had higher than
expected mortality rate. These were mainly young individuals,
with specific comorbidities not identified by the PSI score such
as asthma, COPD; HIV infection, obesity, alcohol and tobacco
use. As some experts have reported, mortality within a certain
score stratum may differ depending on the patient group [23].
It is possible that pneumococcal disease by itself may differ in
previously healthy patients compared to those who present an
underlying condition.
Main complications overlapped with those frequently observed
in patients with CAP admitted to hospital, namely: ICU stay,
presence of pleural effusion, empyema and need for mechanical
ventilation [5].
Mortality rate was 17%, similar to the results obtained by others
in larger series [5,11,13] and most deaths (55%) occurred within
the first 3 days after hospital admission as already has been
described [4,5]. In our study, severity of disease at onset was
the most important factor associated with death. The presence
of severe symptoms such as dyspnea, hypotension or altered
mental status, may suggest organ dysfunction, indicating early
signs of sepsis. As others have observed, age was found to be an
important marker of poor prognosis, mostly in patients over 80
years of age [5,24].
Penicillin resistance is not a problem in our region, so we can
continue using βeta-lactams, alone or combined for treatment
of BPP.
This study has several limitations. The study was performed
in a single center, in a small city then generalizibility of this
data may be limited. Since the study was performed during a
prolonged period of time, the local pactice for therapy of BPP
may have changed and affected the clinical outcomes. In this
study S. pneumoniae serotyping was not performed.
In conclusion we found that BPP is a common infection with a
considerable mortality, mostly after the first days of onset of the
disease. Deaths were associated with increased age, increased
severity of disease at onset and leukopenia.
We believe that a large-scale collaborative epidemiological
study is needed in the region to gain further insight related to
circulating pneumococcal strains. This knowledge would allow
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us to improve the use of available pneumococcal vaccines. We
must not forget that surveillance strategies focusing on BPP,
underestimate pneumococcal disease burden and hence the true
benefits of pneumococcal immunization in adults.
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